Lapozan

Quick links to important sections

Lapozan

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lapozan

Quick Facts

Property Description
Active ingredient Olanzapine
Form Tablet, Orally Disintegrating Tablet (ODT), Intramuscular Injection
Pharmacological class Atypical Antipsychotic (Second-Generation)
Common use Stabilization of mood, behavior, and thought processes
Origin Synthetic, Thienobenzodiazepine derivative

Lapozan: Defining the Atypical Antipsychotic

Lapozan is a prescription medication whose single active component is the synthetic compound Olanzapine. It is chemically classified as a Thienobenzodiazepine derivative and belongs to the broader group of Antipsychotic drugs. More specifically, Lapozan is recognized as a Second-Generation or Atypical Antipsychotic, featuring a unique receptor binding profile compared to older agents. The drug is typically positioned for the adult patient group requiring management of complex psychiatric conditions. The overarching purpose of this medication is to help stabilize disturbances in mood, behavior, and thinking by modulating the chemical signaling within the brain. This action is directed toward maintaining emotional and perceptual stability.


Composition, Forms, and Therapeutic Aim

The physical identity of Lapozan is defined by its formulation as a single-ingredient product across multiple dosage forms, administered either orally or by intramuscular injection. These forms include the standard Oral Tablet, the specialized Orally Disintegrating Tablet (ODT), and a preparation intended for injection. The ODT form is a key feature, offering a practical advantage for patients requiring a rapidly dissolving option. Lapozan's overall therapeutic aim is rooted in its function as a selective monoaminergic antagonist, which means it helps regulate key neurotransmitters, including Dopamine and Serotonin. This mechanism helps restore a more regulated balance of chemical activity in the central nervous system, thereby stabilizing disturbances in thought processes and perception.

What side effects are possible with Lapozan?

Possible Side Effects and Safety Information

Lapozan's safety profile, as documented in official government regulatory sources (e.g., FDA, EMA), details adverse reactions organized by frequency and affected organ system.

Adverse Reaction Scope

Category Description / Listing (Strictly Regulatory Terminology)
Key Adverse Reaction Categories Metabolic changes (weight gain, hyperglycemia, dyslipidemia), nervous system effects (somnolence, akathisia, tremor), and vascular instability (orthostatic hypotension).
Frequency Classification Very Common (ge 1/10): Weight gain, somnolence (including sedation), and elevated plasma prolactin levels. Common (ge 1/100 to <1/10): Dizziness, orthostatic hypotension, dry mouth, increased appetite, asthenia (weakness), akathisia, tremor, dyskinesia, and transient elevations of hepatic aminotransferases (ALT/AST).

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight specific serious adverse reactions and safety limitations:

  • Serious Adverse Reactions: These include Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia (TD) (a risk associated with cumulative duration of treatment), and Hyperglycemia/Diabetes Mellitus, which in some cases has been associated with ketoacidosis or coma. Seizures and Venous Thromboembolism are also documented as potential risks.
  • Metabolic Monitoring: Due to the risk of Metabolic Changes (hyperglycemia, dyslipidemia, and weight gain), labels specify that patients should undergo fasting blood glucose and lipid testing at the beginning of and periodically during treatment.
  • Population-Specific Limitations: Lapozan is not approved for use in older adults with dementia-related psychosis due to an increased risk of death and cerebrovascular adverse events (e.g., stroke). The adolescent population may experience a greater magnitude of weight gain and dyslipidemia compared to adults.
  • Orthostatic Hypotension: This event, associated with dizziness upon standing, is noted as being more common during initial dose titration.

This structured safety information ensures that all officially documented risks are clearly communicated according to regulatory standards.

Overdose and Emergency Response

A Lapozan overdose may manifest through severe effects on the Central Nervous System (CNS) and vital organs, requiring immediate medical attention as outlined by regulatory guidance.

Documented Overdose Manifestations

Documented clinical signs of overdose include profound somnolence, drowsiness, slurred speech (dysarthria), agitation, delirium, and ataxia. Cardiovascular effects such as tachycardia and significant hypotension are also noted, alongside autonomic symptoms like miosis and anticholinergic effects. In severe cases, the presentation may escalate to life-threatening outcomes, including severe respiratory depression and coma; fatal outcomes have been reported following acute ingestions.

When to Seek Urgent Help

If an overdose is suspected or any of the documented symptoms appear, individuals must seek immediate medical attention and contact a certified poison control center. Management relies entirely on intensive supportive treatment, as no specific antidote for Lapozan is known according to regulatory prescribing information. Treatment focuses on establishing and maintaining a patent airway, ensuring adequate ventilation, and stabilizing cardiovascular function.

Continuous observation and monitoring, including continuous cardiac monitoring, are essential and must continue until all signs and symptoms have fully resolved. Overdoses in children are officially associated with more significant adverse effects compared to adults, necessitating more immediate intervention.

Therapeutic Uses of Lapozan

What Lapozan Treats: Main Uses and Benefits

Lapozan is used in situations involving certain distressing symptoms related to major mental health conditions. It is commonly used across conditions presenting with acute episodes and recurrent manifestations. The core indications include Schizophrenia, Bipolar I Disorder (managing manic, mixed, and recurrent episodes), and Treatment-Resistant Depression, typically when used alongside other agents.

It is applied across domains where additional symptomatic support is needed for symptoms such as hallucinations, delusions, severe thought disorganization, and extreme emotional highs (mania). Lapozan may play a role in managing these symptom clusters that may become intense or disruptive. This supportive role offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

“It may contribute to improved comfort during these periods, supporting the patient during difficult episodes by easing distress, and assisting with maintaining a sense of stability when symptoms are more noticeable.”

The medication is considered relevant when short-term symptomatic assistance is needed, such as managing episodes of severe acute agitation associated with both manic and psychotic states. Applied in scenarios where additional management of discomfort is required, it may assist with maintaining functional stability during symptomatic periods.


QuickFact Block

Quick Fact: Relief for Symptom
Primary Focus Disturbances in thought, perception, and severe mood extremes
Acute Context Managing episodes of severe psychomotor agitation
Long-Term Role Supporting the management of recurrent manic and depressive manifestations
Core Patient Benefit Easing overall symptom burden and assisting with functional stability

Regulatory References

  1. European Medicines Agency (EMA) overview of Zyprexa

Eligibility and Restrictions for Use

Lapozan (olanzapine) is subject to strict eligibility rules based on official regulatory documentation. It is contraindicated in patients with a known hypersensitivity to the drug or those with or at risk for narrow-angle glaucoma.

Population Status Regulatory Rule Practical Implication
Dementia-Related Psychosis Use is not approved and not recommended; associated with increased mortality and cerebrovascular events. Must not be used in elderly patients with this condition.
Children/Adolescents Safety and efficacy are not established below a certain age (e.g., 13 or 18 years, depending on the specific use and regulatory source). Use is restricted or not recommended for the youngest age groups.
Hepatic Impairment Requires caution; lower starting dose should be considered in moderate impairment. Use is conditional; requires specific clinical monitoring and dosage consideration.
Pregnancy/Lactation Use during pregnancy, especially the third trimester, carries a risk of neonatal withdrawal symptoms. Excreted in breast milk. Use is permitted only after a careful benefit-risk evaluation by a healthcare provider.

What should I know about interactions with other medicines?

Lapozan (Olanzapine) interacts with other products primarily due to its effects on the central nervous system (CNS) and its metabolic pathways.

Potential Drug-Drug Interactions

Mechanism/Category Interacting Medicines/Products
CNS Depression Alcohol and other centrally acting medicines (e.g., Benzodiazepines, Opioids). Caution is required due to potential additive sedative and hypotensive effects.
Metabolic Pathway (CYP1A2) Fluvoxamine (a strong CYP1A2 inhibitor) or similar agents may increase Lapozan’s concentration, necessitating a dose reduction of Lapozan. Smoking (an inducer) can decrease Lapozan’s concentration.
Specific Combinations Valproate is associated with an increased risk of neutropenia when used concomitantly. Combination use with Lithium and Fluoxetine is referenced in official labeling.
Cardiac/Anticholinergic Medicines known to increase the QTc interval must be used with caution, particularly in patients with cardiac risk factors or the elderly. Caution is also advised with other anticholinergic drugs due to potential additive effects.
Dopamine Effects Lapozan may antagonize the effects of dopamine agonists due to its inherent dopamine receptor blocking activity.

Regulatory Restrictions and Warnings

Lapozan should be used cautiously in patients who have a history of seizures or are subject to factors that may lower the seizure threshold. Patients on concomitant therapy with drugs that affect coagulation (e.g., NSAIDs, Aspirin, Warfarin) may have an enhanced risk of bleeding.

Mechanism of Action

How Lapozan Works

Lapozan's mechanism involves engagement with multiple distinct mechanistic domains, resulting in altered physiological signaling.


Dual Neurotransmitter Stabilization: Serotonin and Dopamine

Lapozan primarily functions as a high-affinity antagonist at a wide range of receptors, focusing predominantly on Dopamine ( D2) and Serotonin (5 -HT2A) receptors. This dual antagonism modulates activity within the Mesolimbic and Cortical pathways, initiating a cascade that modulates overactive physiological responses and promotes a shift toward a regulated state of chemical signaling in the brain.


Modulation of Central Arousal and Metabolic Pathways

This secondary, yet functionally relevant, mechanistic domain involves high-affinity antagonism at Histamine ( H1) receptors and Muscarinic Cholinergic receptors. This interference with Histamine signaling modulates the central arousal system, leading to a predictable decrease in wakefulness, and functionally alters the body's metabolic programming related to energy substrate utilization.


Autonomic and Vascular Tone Modulation

The molecule also acts as an antagonist on alpha1 adrenergic receptors. This mechanism specifically targets the autonomic nervous system's regulatory pathways, leading to a reduction in peripheral vascular resistance and modulating the regulatory control of vascular tone within the autonomic system.

Dosage and Administration Information

How Lapozan is Used

Lapozan (olanzapine) administration and dosing are based on standardized clinical protocols. This section describes the routes of administration, standard dosing regimens, and required procedural conditions associated with this medication.


Approved Forms and Routes

Lapozan is administered via two primary routes:

  • Oral (PO): Used for long-term and maintenance therapy via the standard Tablet or the Orally Disintegrating Tablet (ODT) form.
  • Intramuscular (IM): Used for rapid, short-term control of acute agitation (Short-Acting Injection) and for specific long-term management (Long-Acting Injection - LAI).

Oral Lapozan may be taken without regard to meals, as absorption is not affected by food.


Official Dosing and Scheduling

Oral Lapozan is typically taken once daily. The standard adult starting dose for schizophrenia is 5 mg to 10 mg once daily, with a maximum recommended dose of 20 mg/day. Dosage adjustments typically occur at minimum intervals of at least 24 hours or one week.

For acute agitation, the Short-Acting IM Injection has a typical initial dose of 10 mg, and a maximum of three doses may be administered in a 24-hour period, with subsequent doses given no sooner than 2 to 4 hours after the previous one.


Population-Specific Use and Special Conditions

Dose adjustments are considered for specific populations:

  • Older Adults (65 years and older): A lower starting oral dose of 5 mg/day should be considered.
  • Hepatic Impairment: A lower starting oral dose of 5 mg/day should be considered.

The Long-Acting IM Injection requires administration in a healthcare setting and a post-injection observation period of three hours.

Recent Clinical Evidence

Lapozan: Recent Clinical Evidence

Research has evaluated the effects of Lapozan in key areas, primarily focusing on schizophrenia, bipolar disorder, and acute agitation. Clinical trials have explored the drug's impact on symptoms and its overall tolerability profile across different patient groups, including adolescents and adults.

Efficacy Studies

Studies examined whether Lapozan was associated with observed reductions in the symptoms of schizophrenia and bipolar I disorder (manic or mixed episodes). In large-scale randomized controlled trials, participant groups receiving Lapozan showed changes in clinical global impression scales and specific symptom severity scores compared to those receiving a placebo or an existing active comparator.

Evidence from trials also investigated the drug’s potential effect on acute agitation associated with these conditions, with some formulations studied for rapid onset of effect within minutes to hours following administration.

Tolerability and Safety Profile

Clinical research protocols included extensive monitoring for a range of potential side effects. Across multiple studies, common adverse events observed were weight gain, somnolence (drowsiness), and increased appetite.

Safety data indicated that metabolic changes, including alterations in blood glucose and lipid levels, were a significant area of focus during both short- and long-term research. Subgroup analyses noted that the magnitude and incidence of weight and prolactin changes were greater in adolescent participants compared to adult participants in the study populations.

Key Studies & References

  1. The evidence for pharmacological treatment of neuropathic pain: A systematic review and meta-analysis of randomized, placebo-controlled trials
  2. Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy

Frequently Asked Questions (FAQ)

Common questions about Lapozan (FAQ)


Q: What happens if I stop taking Lapozan suddenly?

A: Official guidance advises against suddenly stopping this medication. A healthcare provider typically reduces the dose gradually if discontinuation is required, which is consistent with regulatory advice. This process is recommended to help prevent potential withdrawal symptoms, which may include nausea, sweating, and difficulty sleeping.

Q: How long can a person safely stay on Lapozan?

A: Regulatory studies have been conducted to assess the drug's safety and effectiveness for long-term use, including for maintenance therapy over periods of up to six years. The duration of treatment is typically determined based on the clinical assessment of the underlying condition and needs.

Q: Does taking Lapozan affect my ability to drive or operate machinery?

A: This medicine may cause drowsiness (somnolence) or make it difficult to concentrate. Official patient information warns that individuals who experience these effects are advised to avoid driving or operating tools and machinery.

Q: Is it common to feel tired when starting Lapozan?

A: Yes, official regulatory documents list somnolence (drowsiness or sleepiness) and fatigue as common or very common side effects. This means these effects are frequently reported by patients, particularly when starting the medicine.

Q: Do the side effects of Lapozan usually go away after a while?

A: Official sources note that some common adverse effects, such as dizziness upon standing (orthostatic hypotension), may be most pronounced during initial dose adjustments. Many reported effects may be temporary; however, certain serious risks are associated with long-term use.

Q: Can Lapozan cause long-term health issues?

A: Regulatory information notes that long-term use of this medicine is associated with a risk of metabolic changes, such as increases in blood sugar, blood lipids, and weight gain. There is also a risk of developing involuntary movement disorders, such as Tardive Dyskinesia, which is often associated with cumulative exposure.

Q: What if I accidentally take more Lapozan than recommended?

A: In cases of taking more than the prescribed amount, official medical guidance specifies that immediate medical attention is necessary. Taking too much Lapozan may lead to serious side effects, which can include severe drowsiness, fast heart rate, agitation, or a coma.

Q: Does Lapozan have a risk of dependence or addiction?

A: Lapozan is not classified as a controlled substance by regulatory bodies, and official prescribing information does not list dependence or addiction as a common risk. Scientific literature has examined the potential for non-medical use or misuse in certain populations.

Q: Why do some people need to avoid Lapozan?

A: Lapozan is not suitable for everyone. It is contraindicated (should not be used) if a person has a known allergy to the drug or has a condition called narrow-angle glaucoma. Additionally, it is not approved for use in older adults who have dementia-related psychosis.

Q: What if I don't see the expected benefit from Lapozan right away?

A: Clinical trials measure the full effects of the medicine over periods of weeks and months, not just days. Official patient guidance recommends continuing the medication as prescribed, even if immediate symptom improvements are not noted, as effects are measured over weeks or months.

Q: Does Lapozan interact with contraceptives?

A: Regulatory interaction data indicates that certain components found in some oral contraceptives, such as ethinyl estradiol, may increase the level of Lapozan in the body. This could potentially increase the chance of experiencing side effects. Lapozan is not noted to affect the effectiveness of contraceptives itself.

Q: What does it mean if I miss a dose of Lapozan?

A: Official patient guidance recommends taking the missed dose as soon as it is remembered. If it is almost time for the next scheduled dose, the advice is to skip the missed dose and resume the usual schedule to avoid taking two doses close together.

Q: Can Lapozan affect my mood or behavior?

A: Official safety information advises that this medicine may be associated with side effects such as agitation, irritability, and other abnormal behaviors. It may also be associated with serious behavioral changes, including suicidal thoughts or tendencies.

Q: What counts as a severe reaction to Lapozan?

A: Regulatory documents list several serious adverse reactions. These include life-threatening conditions like Neuroleptic Malignant Syndrome (NMS), severe metabolic changes, and a rare but serious skin reaction known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Q: Can Lapozan interfere with my other health conditions?

A: Yes, regulatory precautions advise special consideration for patients with a history of certain health issues. Caution is advised for patients with a history of seizures, certain cardiac risk factors, and those with hepatic (liver) or renal (kidney) impairment.

Q: Are there any specific lifestyle changes mentioned in relation to taking Lapozan?

A: Regulatory patient information notes that this medicine can make it harder for the body to cool down. Therefore, precautions are advised regarding exposure to heat. Guidance on hydration is often referenced in official information.

Q: Can Lapozan cause trouble sleeping?

A: The most common reported effect related to sleep is drowsiness (somnolence). However, postmarketing reports also list insomnia, which is difficulty falling asleep or staying asleep, as a possible side effect.

Q: Are there any known interactions between Lapozan and herbal supplements?

A: Official patient information advises exercising caution with herbal remedies, particularly those known to cause sleepiness or dizziness. Cannabidiol (CBD) is specifically noted in some guidance as a supplement that might affect how the medicine works in the body.

Q: Is Lapozan safe for use during pregnancy?

A: Safety has not been formally established for use throughout pregnancy. Regulatory documents specifically note that infants exposed to antipsychotic drugs during the third trimester are at risk for withdrawal symptoms or abnormal muscle movements after delivery.

Q: Can Lapozan be taken while breastfeeding?

A: Regulatory information confirms that the drug is excreted into human milk. The decision to use this medicine while breastfeeding is made by a healthcare provider after a careful benefit-risk assessment, and monitoring of the exposed infant is often necessary.

Q: Is Lapozan approved for use in children?

A: Lapozan is approved by regulatory bodies to treat schizophrenia and acute manic or mixed episodes of bipolar I disorder in adolescents aged 13 years and older. Use is generally restricted or not recommended for children younger than 13 years for specific uses.

Q: Are there specific age groups that cannot use Lapozan?

A: Yes. The medicine is not approved for use in older adults who have dementia-related psychosis. Use is also generally restricted or not recommended for children younger than 13 years for specific uses.

Q: Do official documents mention anything about Lapozan and liver problems?

A: Yes. Regulatory documents advise caution and consideration of a lower starting dose for patients with hepatic (liver) impairment. Official safety data also notes that transient, or temporary, elevations of liver enzymes have been reported.

Q: Does Lapozan cause weight gain?

A: Yes. Official regulatory documents list weight gain as a very common side effect. This means it may affect 1 in 10 people or more. The drug is associated with a risk of metabolic changes, including weight gain.

Q: Does Lapozan need to be taken at a specific time of day?

A: Official information states that oral Lapozan is typically taken once daily. Consistency in the time of administration is typically noted as important.

Q: Why is Lapozan prescribed instead of other similar medications?

A: Lapozan is classified as an atypical antipsychotic. It is noted in regulatory sources for its unique receptor binding profile, which involves primary action on both dopamine and serotonin receptors. This unique mechanism is one factor considered during treatment selection.

Q: Is Lapozan the same as [Name of Competitor Drug]? Who is it for?

A: Lapozan's active ingredient is Olanzapine, a synthetic compound classified as an Atypical Antipsychotic. While it belongs to the same class as other medicines, its specific chemical structure and action are unique to Olanzapine. Eligibility for use is restricted for certain age groups, such as the very young or older adults with dementia-related psychosis.

Q: Can I take Lapozan with other prescription medicines?

A: Official documents describe many potential drug-drug interactions, which means that the effects of Lapozan or the other medicine could be altered when taken together. It is recommended that all current prescription and non-prescription medicines be reviewed by the prescriber before starting this medicine.

Q: What drug classes are known to interact with Lapozan?

A: Drug classes noted for interaction in regulatory documents include medicines that affect the central nervous system (CNS) like alcohol or sedatives. Caution is also advised with medicines that affect the CYP1A2 metabolic enzyme, or those that can increase the QTc interval (affecting heart rhythm).

Q: Can people with kidney issues take Lapozan?

A: Small studies indicate no major change in how the drug is processed in patients with renal (kidney) impairment. However, because clinical experience is limited in this population, regulatory documents state that a lower starting dose should be considered for people with kidney issues.

How should Lapozan be stored and disposed of?

How to Store and Dispose of Lapozan?

This medication must be stored according to strict regulatory requirements to maintain its stability and effectiveness. The product must be kept in the refrigerator, maintained between 2 C and 8 C (36 F and 46 F), and must not be frozen. The original package must be used for storage to protect the medication from light.

For reconstituted forms, the in-use stability is limited. The reconstituted suspension, when filled into an infusion bag, is chemically and physically stable for up to 8 hours when stored at a temperature not exceeding 25 C.

To ensure safety, keep Lapozan out of the reach of children at all times. Disposal of any unused or expired medication must follow official guidelines, typically involving a drug take-back program. If a take-back program is unavailable, follow the specific instructions documented for proper disposal in the trash or by flushing, as designated by regulatory agencies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lapozan found in:

A-Z Index: